BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 20705614)

  • 1. Patterns of expression of DNA repair genes and relapse from melanoma.
    Jewell R; Conway C; Mitra A; Randerson-Moor J; Lobo S; Nsengimana J; Harland M; Marples M; Edward S; Cook M; Powell B; Boon A; de Kort F; Parker KA; Cree IA; Barrett JH; Knowles MA; Bishop DT; Newton-Bishop J
    Clin Cancer Res; 2010 Nov; 16(21):5211-21. PubMed ID: 20705614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival.
    Conway C; Mitra A; Jewell R; Randerson-Moor J; Lobo S; Nsengimana J; Edward S; Sanders DS; Cook M; Powell B; Boon A; Elliott F; de Kort F; Knowles MA; Bishop DT; Newton-Bishop J
    Clin Cancer Res; 2009 Nov; 15(22):6939-46. PubMed ID: 19887478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
    Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
    J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
    Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
    Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High expression of DNA repair pathways is associated with metastasis in melanoma patients.
    Kauffmann A; Rosselli F; Lazar V; Winnepenninckx V; Mansuet-Lupo A; Dessen P; van den Oord JJ; Spatz A; Sarasin A
    Oncogene; 2008 Jan; 27(5):565-73. PubMed ID: 17891185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA repair and replication proteins as prognostic markers in melanoma.
    Song L; Robson T; Doig T; Brenn T; Mathers M; Brown ER; Doherty V; Bartlett JM; Anderson N; Melton DW
    Histopathology; 2013 Jan; 62(2):343-50. PubMed ID: 23020778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cellular markers based on DNA damage and repair (BER, MMR), expression of MLHI, MSH2, FasR, and cell death of lymphocytes as predictive parameters for clinical response to chemotherapy of melanoma].
    Tronov VA; Artamonov DN; Abramov ME; Gorbacheva LB
    Tsitologiia; 2011; 53(1):10-6. PubMed ID: 21473113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma.
    Khunger A; Piazza E; Warren S; Smith TH; Ren X; White A; Elliott N; Cesano A; Beechem JM; Kirkwood JM; Tarhini AA
    PLoS One; 2021; 16(1):e0245287. PubMed ID: 33428680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential Prognostic Predictors and Molecular Targets for Skin Melanoma Screened by Weighted Gene Co-expression Network Analysis.
    Chen S; Liu Z; Li M; Huang Y; Wang M; Zeng W; Wei W; Zhang C; Gong Y; Guo L
    Curr Gene Ther; 2020; 20(1):5-14. PubMed ID: 32416689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma sentinel node biopsy and prediction models for relapse and overall survival.
    Mitra A; Conway C; Walker C; Cook M; Powell B; Lobo S; Chan M; Kissin M; Layer G; Smallwood J; Ottensmeier C; Stanley P; Peach H; Chong H; Elliott F; Iles MM; Nsengimana J; Barrett JH; Bishop DT; Newton-Bishop JA
    Br J Cancer; 2010 Oct; 103(8):1229-36. PubMed ID: 20859289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effectiveness of DNA repair and expression of MLH1, MSH2 and FASR in lymphocytes of patients with chemotherapy-responsive, disseminated cutaneous melanoma].
    Tronov VA; Artamonov DN; Abramov ME; Gorbacheva LB; Lichinitser MR
    Vopr Onkol; 2011; 57(2):165-72. PubMed ID: 21809660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy.
    Kang J; D'Andrea AD; Kozono D
    J Natl Cancer Inst; 2012 May; 104(9):670-81. PubMed ID: 22505474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
    Dummer R; Hauschild A; Santinami M; Atkinson V; Mandalà M; Kirkwood JM; Chiarion Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Lesimple T; Plummer R; Dasgupta K; Gasal E; Tan M; Long GV; Schadendorf D
    N Engl J Med; 2020 Sep; 383(12):1139-1148. PubMed ID: 32877599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential role of cyclin F mRNA expression in the survival of skin melanoma patients: Comprehensive analysis of the pathways altered due to cyclin F upregulation.
    Gagat M; Krajewski A; Grzanka D; Grzanka A
    Oncol Rep; 2018 Jul; 40(1):123-144. PubMed ID: 29767233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profiling of primary cutaneous melanoma.
    Winnepenninckx V; Van den Oord JJ
    Verh K Acad Geneeskd Belg; 2007; 69(1):23-45. PubMed ID: 17427873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melanoma Expression Genes Identified through Genome-Wide Association Study of Breslow Tumor Thickness.
    Fang S; Vaysse A; Brossard M; Wang Y; Deng D; Liu Q; Zhang P; Xu K; Li M; Feng R; Liu H; Dang Y; Chen W; Prieto V; Gershenwald JE; Ross MI; Matejka B; Malke J; Haydu LE; Reveille JD; Sui D; Bassett RL; Koshkina N; Avril MF; Lu M; Wei Q; Demenais F; Amos CI; Lee JE
    J Invest Dermatol; 2017 Jan; 137(1):253-257. PubMed ID: 27506587
    [No Abstract]   [Full Text] [Related]  

  • 17. DNA repair gene expression and risk of locoregional relapse in breast cancer patients.
    Le Scodan R; Cizeron-Clairac G; Fourme E; Meseure D; Vacher S; Spyratos F; de la Lande B; Cvitkovic F; Lidereau R; Bieche I
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):328-36. PubMed ID: 20092964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.
    Hamid O; Schmidt H; Nissan A; Ridolfi L; Aamdal S; Hansson J; Guida M; Hyams DM; Gómez H; Bastholt L; Chasalow SD; Berman D
    J Transl Med; 2011 Nov; 9():204. PubMed ID: 22123319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma.
    Scala S; Ottaiano A; Ascierto PA; Cavalli M; Simeone E; Giuliano P; Napolitano M; Franco R; Botti G; Castello G
    Clin Cancer Res; 2005 Mar; 11(5):1835-41. PubMed ID: 15756007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triptolide induced DNA damage in A375.S2 human malignant melanoma cells is mediated via reduction of DNA repair genes.
    Chueh FS; Chen YL; Hsu SC; Yang JS; Hsueh SC; Ji BC; Lu HF; Chung JG
    Oncol Rep; 2013 Feb; 29(2):613-8. PubMed ID: 23233170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.